<DOC>
	<DOCNO>NCT00431795</DOCNO>
	<brief_summary>DOXORUBICIN recognize one active drug breast cancer , clinical utility limit cumulative dose-dependent cardiac myopathy lead potentially fatal congestive heart failure . Caelyx ( pegylated liposomal doxorubicin ) design reduce cardiotoxicity doxorubicin preserve antitumor efficacy</brief_summary>
	<brief_title>Randomized Phase II Study Epirubicin v Caelyx Pretreated Metastatic Breast Cancer</brief_title>
	<detailed_description>To compare efficacy pegylated liposomal doxorubicin versus epirubicin second line chemotherapy patient advance breast cancer</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Age 1875 year Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Adequate bone marrow function ( Absolute neutrophil count &gt; 1000/mm^3 , Platelet count &gt; 100000/mm^3 , Hemoglobin &gt; 9gr/mm^3 ) Histologically cytologically confirm breast adenocarcinoma No prior anthracyclinebased chemotherapy treatment advance breast cancer No prior chemotherapy ≥ 300mg/m2 doxorubicin ≥ 540mg/m2 epirubicin adjuvant setting At least 4 week interval since prior anticancer treatment Measurable disease define presence least one measurable lesion ( except bone metastasis , ascites pleural effusion ) Life expectancy &gt; 3 month Written inform consent Pregnancy nursing Documented history congestive heart failure ( CHF ) , serious arrhythmia , myocardial infarction ( within 6 month ) Other invasive malignancy except nonmelanoma skin cancer acute infection . Radiation measurable disease ( except brain metastasis ) Progressive brain metastasis accord clinical radiological criterion . Brain metastasis without prior radiation therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Advanced breast cancer</keyword>
	<keyword>Pegylated liposomal doxorubicin</keyword>
	<keyword>Epirubicin</keyword>
</DOC>